Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Broad Spectrum Safety Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers

NCT03035760
View directory record Official record
Conditions
Helminthic Infection
Interventions
Oxfendazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 9, 2026, 9:20 PM EDT
Not listed Phase 2 Interventional

The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome

NCT01966276
View directory record Official record
Conditions
Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME)
Interventions
Methyl-P plus Nutrient Formula, Methyl-P plus Nutrient matched placebos
Drug
Lead sponsor
K-PAX Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Stanford, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 9, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional Results available

Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones

NCT02028559
View directory record Official record
Conditions
Kidney Stones, Nephrolithiasis, Urolithiasis
Interventions
Propulse 1 with C5-2 probe, Propulse 1 with SC-X probe
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

NCT04996264
View directory record Official record
Conditions
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions
Varespladib Methyl, Placebo, Standard of care (SOC)
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
5 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 9, 2026, 9:20 PM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 9, 2026, 9:20 PM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

NCT02527681
View directory record Official record
Conditions
Bacterial Infections
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
Up to 3 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Loma Linda, California • Los Angeles, California • South Bend, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Not applicable Interventional

OSCAR I STUDY - The ONCObind CTC Removal Study

NCT06481397
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
ONCObind (Onco-Seraph) 100 Filter
Device
Lead sponsor
ExThera Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Single Ascending Dose Study

NCT03024034
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

NCT00633152
View directory record Official record
Conditions
Bacterial Infection
Interventions
ceftaroline, linezolid, Aztreonam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 9, 2026, 9:20 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray

NCT05437029
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Q-Griffithsin 3.0, Q-Griffithsin 6.0
Drug
Lead sponsor
Kenneth Palmer
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 9, 2026, 9:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study on Prodovite® VMP35 Supplement on Athletic Performance

NCT04121481
View directory record Official record
Conditions
Athletic Performance
Interventions
Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement, Broad Spectrum Safety
Dietary Supplement
Lead sponsor
Victory Nutrition International, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cornelius, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults

NCT02570074
View directory record Official record
Conditions
Healthy Subjects
Interventions
Fosfomycin
Drug
Lead sponsor
Vance Fowler, M.D.
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 9, 2026, 9:20 PM EDT
Active, not recruiting Phase 1 Interventional

T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation

NCT03180216
View directory record Official record
Conditions
Viral Infections, Bone Marrow Transplant Infection
Interventions
Virus Specific T cells (VSTs)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 9, 2026, 9:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

NCT04610866
View directory record Official record
Conditions
Sickle Cell Disease, Hemolytic Anemia
Interventions
Mitapivat
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

NCT02724085
View directory record Official record
Conditions
Pneumonia
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Safety and Tolerability of a Brightening Treatment Paired With a Skincare Regimen

NCT07501000
View directory record Official record
Conditions
Hyperpigmentation, Skin Ageing, Post Inflammatory Hyperpigmentation, Skin Roughness
Interventions
Brightening Treatment
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
20 Years to 65 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety and PK Study of IV TP-271

NCT03234738
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271, Placebo
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy Evaluation of SMART Camera Treatment Presets for Cutaneous Lesions Using IPL

NCT05755139
View directory record Official record
Conditions
Vascular Lesion, Pigmented Lesions
Interventions
IPL with smart diagnostic handpiece
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

NCT03450187
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Sep 9, 2026, 9:20 PM EDT
Active, not recruiting Not applicable Interventional

Blood Purification for the Treatment of Pathogen Associated Shock

NCT05011656
View directory record Official record
Conditions
Septic Shock
Interventions
Seraph-100 + State of the Art Care, State of the Art Care
Device
Lead sponsor
ExThera Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Brunswick, Georgia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

NCT05122260
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Q-Griffithsin, Placebo
Drug · Other
Lead sponsor
Kenneth Palmer
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 9, 2026, 9:20 PM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
8
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 9, 2026, 9:20 PM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 9, 2026, 9:20 PM EDT